1 Recommendations

1.1 Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:

  • who have had at least 1 prior therapy or

  • who have a 17p deletion or TP53 mutation, and in whom chemo-immunotherapy is unsuitable and

  • only when the company provides ibrutinib with the discount agreed in the patient access scheme.

  • National Institute for Health and Care Excellence (NICE)